Terminated PHASE3 INTERVENTIONAL 2-arm NCT00384293

Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED) (ACHIEVE)

A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK0524A 2g Coadministered With Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery Intima Media Thickening (cIMT) in Patients With Heterozygous Familial Hypercholesterolemia (heFH)

Sponsor: Merck Sharp & Dohme LLC

Conditions Hypercholesterolemia, Familial

Interventions Comparator: niacin (+) laropiprant (MK0524A) Comparator: placebo

Updated 8 times since 2017 Last updated: Sep 28, 2015 Started: Sep 30, 2006 Primary completion: Aug 31, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

Other Hypercholesterolemia, Familial trials with similar outcome

NCT00092833 · Phase PHASE3 · May 2005

Browse all Hypercholesterolemia, Familial trials

Listed as NCT00384293, this PHASE3 trial focuses on Hypercholesterolemia, Familial and remains terminated or withdrawn. Sponsored by Merck Sharp & Dohme LLC, it has been updated 8 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jun 2022 — Jul 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jun 2022 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.